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Background: The aim of this retrospective study was to evaluate the contribution of
fluorine-18-fluoro-deoxyglucose (FDG) positron emission tomography (PET) to the clinical
management and survival outcome of patients (pts) suspected of recurrent ovarian
carcinoma, with the hypothesis that early diagnosis of recurrent ovarian cancer may
improve overall survival (OS).
Methods: Fifty-three FDG PET/CT scans were retrospectively analyzed for 42 pts. CT
and PET/CT findings were confirmed by imaging and clinical follow-up, and/or pathology,
which were considered as the gold standard diagnosis. The treatment plan based on
CT staging was compared with that based on PET/CT findings. Medical records were
reviewed for pts characteristics, progression-free survival (PFS), and OS. PFS and OS
were analyzed using the Cox proportional hazards regression model.
Results: The final diagnosis of recurrence was established pathologically (n=16), or by
a median clinical follow-up of 6.5 years (range 0.5-7.5) after the PET/CT (n=37). PET/CT
provided a higher detection sensitivity (92.2%, 47/51) than CT (60.8%, 31/51) (p<0.001).
Globally, PET/CT modified the treatment plan in 56.6% (30/53) and in 65.2% (15/23)
when the CT was negative prior to PET/CT. In 30 cases, those benefited from a modified
treatment plan, these changes led to the intensification of a previous treatment procedure
in 83.3% (25/30), and to a reduction in the previous treatment procedure in 16.6% of
cases (5/30). The Cox regression multivariate analysis showed that the number of lesions
visualized by CT and presence of lung lesions detected by PET/CT were significantly
associated with PFS (p=0.002 and p=0.035, respectively).
Conclusion: On account of its impact on treatment planning, and especially in predicting
patient outcome, FDG PET is a valuable diagnostic tool for cases of suspected ovarian
cancer recurrence.
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Introduction
Ovarian cancer has the highest mortality of all gynecological
cancers (1). Ovarian carcinoma is usually diagnosed at a late
stage due to the paucity and insidious onset of symptoms (2).
Despite high-response rates after initial treatment, 20–30% of
patients with early-stage disease (stage IA-IIA), and up to 75%
of patients with advanced disease (IIB-IV) present with recur-
rence within 2 years (3). Follow-up protocols usually consist of
a physical examination, evaluation of the serum tumor marker
(CA125), and morphological imaging techniques, such as ultra-
sound (US), computed tomography, and/or magnetic resonance
imaging (MRI). However, these methods suffer certain limita-
tions. Physical examinationmay be imprecise, and elevated values
of CA 125 are sensitive for the early detection of active disease but
do not localize the site of recurrence (4). In addition, conventional
imaging (CI) techniques based on anatomical modifications, such
as the identification of a new abnormal lesion or changes in the
size of a known lesion, may have limited accuracy in the detection
of tumor recurrence. Moreover, CT and MRI imaging (either
soon after treatment or at later stages) are of limited value for
optimally differentiating a recurrence signal from a post-surgical
status, or due to their inability to detect normal-sized lymph node
metastases (5).
Positron emission tomography (PET) with fluorine-18-fluoro-
deoxyglucose (FDG) has been proposed as a way of overcoming
these limitations. It has been found to be highly sensitive for
detecting recurrent ovarian cancer, especially in patients with
an unexplained elevation of serum tumor markers. It offers the
combined benefits of anatomical and functional imaging, and
has been used to localize areas of increased FDG with improved
anatomical specificity, and to exclude disease in sites of residual
structural abnormality (6). A recent study evaluated the clin-
ical impact of FDG PET upon treatment strategy, and found
that accurate localization of ovarian cancer recurrence impacts
both patient outcome and treatment strategy (7). The purpose
of this study was to assess the clinical and therapeutic impact
of FDG PET in women who were suspected of ovarian cancer
recurrence.
Materials and Methods
Patient Population
Patients included retrospectively were of over 18 years of age, with
histologically proven ovarian cancer that was suspected of recur-
rence, and had been treated in our institution between 2006 and
2010. All patients of the institution received written information
on the possibility of use of theirmedical data in retrospective stud-
ies. After initial diagnosis, the patients weremonitored by physical
examination, CA 125 assay, and CT every 6months over a 5-
year period. Recurrent disease was suspected following abnormal
examination results and/or symptoms suggestive of recurrence,
equivocal results on CI, and/or the isolated elevated serum tumor
marker (CA 125). PET scans were acquired only if recurrence
was suspected from the different criteria described above. The
International Federation of Gynecology and Obstetrics (FIGO)
classification was used for clinical staging (8). A minimum of
6months follow-up after the post-treatment PET scan was also an
inclusion criterion for this study.
CT Imaging
CT images were obtained using a Hi-speed CT scanner (GE
Medical Systems, Milwaukee, WI, USA). Patients fasted for 4 h
beforeCT imaging. Scanswere acquired in the craniocaudal direc-
tion, between the diaphragm and the perineum. After a series
of unenhanced sections, all patients received intravenous bolus
injection of contrast medium (Omnipaque 300™, GE Healthcare,
Vélizy-Villacoublay, France) at a rate of 2.5–3mL/s and a volume
of 75–90mL. The Hi-Speed CT scanner generated contiguous
slices measuring 5mm in thickness and reconstruction interval
was 1.25mm.
PET/CT Scanning
Scanning, from the patient’s head to the pelvic floor with their arm
held above their head, was performed using a Siemens Biograph
mCT40 fitted with a 20 cm axial field of view, true of flight
(TOF) feature, and in-plane resolution of 4.4mm in full width
at half maximum (Siemens, Knoxville, TN, USA). Images were
reconstructed with Ultra HD and TOF (3 iterations, 21 subsets).
Patients fasted for at least 4 h before PET acquisition. Fasting
blood glucose, which had to be <7mmol/L, was checked prior to
injection of 3MBq/kg of FDG. Intravenous injection was followed
by a tracer-uptake period of approximately 60min, during which
patients remained seated in a quiet room. Low dose-unenhanced
CT was performed for localization and attenuation correction.
The reformatted, transverse, coronal, and sagittal views were used
for interpretation.
Qualitative Imaging Analysis
CTandPET/CT clinical reports were collected and retrospectively
analyzed. All PET/CT images were interpreted independently
by two nuclear medicine physicians. The observers were aware
of the clinical data and findings obtained with other anatomic
imaging modalities. When abnormal FDG uptake was observed,
its exact anatomical location was indicated on the CT scans. On
PET images, the presence of a relapse tumor was suspected when
accumulation of FDG was moderately to markedly increased, in
comparison with that of comparable normal contralateral struc-
tures or surrounding tissues, excluding physiological bowel and
urinary activity.
For both ethical and practical reasons, not every suspected
involved lesion was evaluated by histology. A gold standard ref-
erence was therefore established based on histology and 6months
follow-up data (significant tumor progression on clinical exam-
ination or on CT according to RECIST Criteria). True-positive
results corresponded to an abnormal image by an imagingmethod
(CT or PET/CT) confirmed by histopathology or follow-up. For
example, foci that were detected by PET/CT, which were not
histologically examined, were considered to be true-positives if
the disease became obvious upon clinical observation or with the
imaging methods during the follow-up. A negative finding on an
imaging method was considered to be false-negative if positive
by histopathology or follow-up. Indeed, a negative finding on an
imaging method that was detected by another imaging method
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and confirmed by histopathology or by a clinical or imaging pro-
gression was considered to be false-negative. True-negative results
corresponded to the absence of an abnormality by an imaging
method, confirmation by a negative tissue biopsy, or lack of recur-
rence during the follow-up. For example, when no abnormality
was found by PET/CT, or when no intervention was performed,
the result was considered to be a true-negative if no disease was
identified by other imaging studies or by clinical observation
during 6months follow-up. Finally, an abnormal result on an
imaging method was considered to be false-positive if negative by
histopathology or by follow-up. Suspicious involved lymph nodes
were followed by CT although their size initially was not enough
RECIST 1.1 criteria. Indeed, their development after treatment or
not treatment has defined their status.
Statistical Analysis
Results are expressed as mean values SD or median (range) in
the case of small group sizes. Qualitative variables were compared
using the Pearson test or the Fisher exact test where necessary
(small sample size). Paired qualitative variables were compared
using the Mac Nemar test. Quantitative variables were com-
pared using the Student’s t-test or the Mann–Whitney U test
where necessary. Survival curves were calculated by means of the
Kaplan–Meiermethod and compared by a log rank test.Multivari-
ate analysis was performed by means of a Cox regression model.
Analyses were performed using SAS 9.1 (SAS Institute Inc., Cary,
NC, USA) and Stata/SE 10 (StataCorp LP, College Station, TX,
USA). All tests were performed at a two-sided significance level of
α= 0.05.
Results
Patient Characteristics
We retrospectively evaluated 42 patients, with a median age of
45.5 years (35–81). For these patients, 53 PET/CTwere performed.
Patient characteristics are described inTable 1. All patients, except
one, had a high risk of relapse. The recurrence was suspected
due to abnormal results by CI in 30/53 PET/CT (56.6%) and
an isolated elevated serum tumor marker CA 125 was observed
in 23/47 PET/CT (48.9%). Recurrence was histopathologically
confirmed in 30% (16/53) of cases, or by clinical follow-up for
other patients, with amedian clinical follow-up of 6.5 years (range
0.5–7.5) after PET/CT. PET/CT scans were not repeated during
the follow-up even in cases of negative PET/CT results.OnlyCTor
MRI was repeated. The median delay between PET/CT and initial
treatment was 2.72 years (range 0.2–21.1).
Imaging Results
Table 2 shows the patient-based performance of whole-body
PET/CT and CI.Whole-body PET/CT provided higher sensitivity
and accuracy compared to CI (p< 0.001), especially with a sensi-
tivity of 92.2% for PET/CT compared to 60.8% for CI. The four
PET/CT false-negative results were local recurrences, all of which
were also negative by CT.
For patients with elevated tumor marker CA125 (n= 47), the
sensitivity of PET/CT was 91.3% (42/47), compared to 50%
(23/46) for CI. PET/CT accurately diagnosed a recurrent disease
TABLE 1 | Patient characteristics before each FDG PET (53 examinations).
Characteristics Value
Number of patients 42
Number of FDG PET 53
Median years (range) 59.3 (35.1–81)
Tumor histology
Adenocarcinoma 37
Borderline 3
Serous 1
Granulosa cells 1
FIGO stage
II 1
III 41
CA 125 level before FDG PET (Normal <1.5µg/L)
Positive 47
Negative 6
Time from previous treatment (months)
Median (range) 33 (2–253)
TABLE 2 | Performance of FDG PET/CT and conventional imaging to detect
recurrence of ovarian cancer.
Performances PET/CT
whole body
Conventional
imaging
p
N 53
True-positive (n) 47 31
True-negative (n) 2 0
False-positive (n) 0 2
False-negative (n) 4 20
Sensitivity (%) 92:2 60:8 <0:001
Specificity (%) 100 – 0:333
PPV (%) 100 93:9 0:167
NPV (%) 33:3 – 0:046
Accuracy (%) 92:5 52:8 0:01
TABLE 3 | Frequency of abnormal FDG PET findings by the site of involve-
ment.
Sites of recurrence Frequency
Lymph nodes 38 (71:7%)
Supradiaphragmatic 5
Supra and infradiaphragmatic 12
Pelvis 7 (13:2%)
Liver 10 (18:9%)
Bone 2 (3:7%)
Lung 4 (7:5%)
Peritoneal lesion 16 (30:2%)
in 91.5% of patients (43/47) compared to 48.9% (23/47) by CI
(p< 0.001). Themost frequent site of recurrence was in the lymph
nodes (as described in Table 3; Figure 1).
Clinical Impact of PET/CT
Table 4 summarizes the changes in patient management based on
PET/CT results. The confirmation of recurrence sites by biopsy
was not considered as a modified treatment plan. Therefore, the
therapeutic strategy was modified in 30/53 (56.6%) cases, and in
65.2% (15/23) when CI was negative. In 30 cases, those benefited
from a modified treatment plan, these changes led to the use of
a previously unplanned therapeutic procedure in all cases, to the
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FIGURE 1 | Seventy-two-year-old patient suspected of pelvic recurrence of ovarian cancer. The CT was negative and CA125 normal (12U/mL for N<35),
but with increasing kinetic. PET/CT found nodal retroperitoneal and pelvic abnormalities.
TABLE 4 | Changes in patient management based on the PET/CT results.
Treatment proposed
before PET FDG
Therapeutic strategy decided
after PET FDG
11 (Surgery) 7 (Chemotherapy)
1 (Surgery and chemotherapy)
1 (Extended surgery)
2 (Surveillance)
3 (Chemotherapy) 2 (Surgery)
1 (Surveillance)
1 (Radiotherapy) 1 (Chemotherapy)
15 (Surveillance) 13 (Chemotherapy)
1 (Surgery)
1 (Surgery and chemotherapy)
intensification of a previous treatment procedure in 83.3% (25/30)
of cases, and to a reduction in previous treatment procedures
in 16.6% of cases (5/30). In true-positive cases, the treatment
showed decreases lesions size (for lesion without possible biopsy
by ethics), decreases of biomarker with treatment, decreases of
not significant nodes size with RECIST 1.1 but positive for
PET/CT and sometimes appearance of significant lesions on CT
(whereas PET/CT was earlier positive) in case of non-responders
to treatment.
Survival Analysis
The impact of several variables on patient survival [progression-
free and overall survival (OS)] were analyzed: age, increased
CA125, the number of CT lesions, the number of PET/CT lesions,
and semi-quantitative indexes, such as SUVmax, SUVmean, SUV-
peak, and total lesion glycolysis (TLG).
Lung lesions detected by FDG or abnormal CT were predictive
of progression free survival (PFS) (Figure 2). The PFS was better
not only for patients with PET findings with lung foci (p= 0.035)
but also for patients with abnormal CT than with normal CT
(p= 0.002), as described in Table 5. The 1-year PFS was 42.9%
for patients with PET findings without lung lesions, and 0% with
lung metastases (p= 0.049).
Bone or lung lesions detected only by FDG PET were pre-
dictive of OS, whereas CI was not contributive (Figure 3). The
OS was better for patients with PET findings without FDG foci
corresponding to lung or bone metastasis (unknown by CI) than
with PET findings, with lung foci (p= 0.034) or with bone foci
(p= 0.020), as described in Table 6. The 1-year OS was 90.2% in
patients with PET findings without bone lesions, and 50.0% with
bone metastases.
Discussion
To our knowledge, this study is the first of its kind to extensively
follow-up suspected recurrent ovarian carcinoma by PET/CT
imaging, with the goal of determining prognostic factors for
disease-free and OS, as well as the clinical impact of FDG PET in
this indication. There are twomajor findings in this current study:
(1) the absence of lung recurrence sites by PET/CT imaging was
independent and prognostic of a good PFS (42% 1-year PFS) and
(2) the absence of bone lesions by whole-body FDG PET was an
independent and robust prognostic factor (90.2% 1-year OS).
Of all the variables analyzed (age, CA 125, number of target
lesions on CT, abnormalities on CT, number of target lesions
on PET/CT, abnormalities on PET/CT, lymph node, peritoneal,
liver, pelvis, lung, or bone metastases, as well as semi-quantitative
indexes, such as SUVmax, SUVmean, SUVpeak, and TLG), lung
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FIGURE 2 | Kaplan–Meier curves for progression-free survival for patients with a suspected ovarian cancer recurrence according to the presence or
absence of lung lesions by FDG PET (A), and the presence or absence of lesions by CT (B).
TABLE 5 | Uni- and mutivariate analyses for the determination for factors
prognostic of progression-free survival (PFS) in recurrent ovarian cancer.
Univariate analysis Multivariate analysis
Parameters HR (95% CI) p-Value HR (95% CI) p-Value
Age 0.99 (0.96–1.02) 0.514 – –
CA 125>35 vs. 35 2.47 (0.86–7.09) 0.093 – –
FDG PET foci
>0 vs. 0 0.79 (0.33–1.87) 0.590 – –
Lung lesion >0 vs. 0 2.77 (0.96–7.96) 0.059 3.14 (1.08–9.11) 0.035
CT foci 0 vs. >0 0.39 (0.21–0.71) 0.002 2.68 (1.45–4.96) 0.002
SUVmax 1.01 (0.95–1.06) 0.891 – –
SUVmean 1.02 (0.94–1.10) 0.680 – –
SUVpeak 1.01 (0.95–1.08) 0.676 – –
TLG 1.00 (0.99–1.00) 0.804 – –
lesions detected only byPET/CTwere significantly associatedwith
PFS, while bone or lungmetastases detected only by PET/CTwere
associated with OS. The semi-quantitative index of PET/CT has
no prognostic value in our study. One possible explanation is the
heterogeneity of the population studied, with one ormore relapses
per patient, different types of treatments, and different disease
resistance to treatment. The results of our study are consistentwith
that ofHebel et al. (9). They did not find any significant association
between SUVmax and the specific survival in patients with a
positive PET/CT scan, nor a significant difference between the
SUVmax of the most intense lesion or the number of suspicious
lesions on PET/CT scan between patients who responded or not to
therapy. On the contrary, the study of Sala et al. showed a possible
prognostic role for SUVmax (10). For patients with low-grade
serous ovarian cancer, the TLG could be prognostic for survival
after relapse, according to a study by Takeuchi (11). In their study,
multiple recurrence was associated with poorer PFS than single-
lesion recurrence, while CA 125 and SUVmax were not significant
predictors of PFS or OS. For our group of patients, TLG was not
associatedwith either disease-free survival orOS (12). In the study
by Levy et al., CA 125 level of recurrence and the pattern of CA
125 elevation were significantly associated with PFS and OS by
univariate analysis, while in the multivariate analysis increases in
CA 125 above normal levels was an independent predictor of PFS
and of OS (Levy). In our study, CA 125 had no prognostic value.
Sala et al. found that the number, size, and SUVmax of recurrent
ovarian cancer lesions in the peritoneum and distant lymph nodes
were significantly associated with OS and PFS [Sala 8]. The recent
study of Kim et al. found that the platinum-free interval, type of
second-line treatment,metabolic tumor volume, andTLGwere all
significant prognostic factors for post-relapse survival (13).
According to clinical guidelines, when recurrence is suspected,
the second step after the determination of CA 125 levels is the
CT scan (14–16), with MRI as an alternative if the CT is con-
traindicated (17). However, several studies have shown the diag-
nostic superiority of PET/CT over CT. There are some limitations
of PET/CT, including the non-specific nature of tracer-uptake,
which can accumulate in sites of inflammation and infection,
whichmay be detected as false-positive (18). In addition, PET/CT
has a limited ability to detect small lesions, particularly for those
<5mm, with a false-negative rate of 5–10% (19, 20). PET/CT
resolution is currently around 4mm, and even with technical
improvements, it cannot drop below 2mm because the free path
of a positron will always leave doubt as to its place of origin
(21). Sometimes, the fusion of PET and CT images is not perfect,
because of the physiological digestive peristalsis. False-negative
results are possible in clear cell and mucinous ovarian cancer,
and in necrotic or cystic lesions (22–24). Thus, in a prospective
study, Risum et al. evaluated the sensitivity and specificity of US,
CT, and PET/CT in the diagnosis of recurrence in 60 patients
(25). While the specificity was the same (90%) for the three tests,
sensitivity was 97% for PET/CT, 81% for CT, and 66% for US.
In addition, PET/CT was superior to single recurrence detection
and found recurrence in 50% of patients with negative CT and
multifocal recurrence in 42% of cases with isolated recurrence on
CT. The meta-analysis of Gu et al., who compared the CA 125,
PET, PET/CT, and MRI for the diagnosis of recurrent ovarian
cancer in 882 patients found a higher sensitivity for PET/CT (91%)
and greater specificity for CA 125 (5). The retrospective study of
Antunovic et al. showed better sensitivity (82 vs. 69%), specificity
(87 vs. 47%), and accuracy (83 vs. 66%) of PET/CT compared
to CI, and better sensitivity compared to CA 125 (83 vs. 59%).
Furthermore, the sensitivity of the PET/CTwas not affected in this
tumor differentiation study (26). PET/CT combined with con-
trast iodine injection was superior in the detection of recurrence
compared to PET/CT without injection in the study by Kitajima
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FIGURE 3 | Kaplan–Meier curves for overall survival of patients with a suspected ovarian cancer recurrence according to the presence or absence of
lung lesions on FDG PET (A), and the presence or absence of bone lesions on FDG PET (B).
TABLE 6 | Uni- and mutivariate analyses for the determination of factors
prognostic for overall survival (OS) in recurrent ovarian cancer.
Univariate analysis Multivariate analysis
Parameters HR (95% CI) p-Value HR (95% CI) p-Value
Age 1.02 (0.98–1.04) 0.298 – –
CA 125>35 vs. 35 1.67 (0.59–4.70) 0.970 – –
FDG PET foci
>0 vs. 0 1.15 (1.02–1.29) 0.023 – –
Lung lesion >0 vs. 0 2.93 (1.03–8.34) 0.044 3.12 (1.09–8.89) 0.034
Bone lesion >0 vs. 0 5.53 (1.22–25.12) 0.027 6.09 (1.33–27.83) 0.020
CT foci >0 vs. 0 0.63 (0.34–1.15) 0.129 – –
SUVmax 1.02 (0.97–1.07) 0.415 – –
SUVmean 1.00 (0.92–1.10) 0.904 – –
SUVpeak 1.03 (0.97–1.09) 0.308 – –
TLG 1.00 (0.99–1.00) 0.196 – –
et al. (121 patients), with a sensitivity of 87 vs. 78% (27). Contrast
iodine injections were not performed in our PET/CT analysis.
The diagnostic value of PET/CT in our study (sensitivity 97.5%,
47 patients) was similar to that of MRI in the study of Sanli
et al. (28), and even better for the detection of peritoneal carci-
nomatosis lesions of between 0.5 and 2 cm (p< 0.05). PET/CT
has good sensitivity in detecting lymph node metastases (29),
especially supra-diaphragmatic lesions (30). In our study, in 71.7%
of cases, there were lymph nodes metastases, with 32% of cases
with supra-diaphragmatic lesions. A negative FDG PET/CT has
a high-negative predictive value (9). The results of our study are
comparable to the literature, with a good performance of PET/CT
(Table 7) (5, 6, 9, 11, 23, 25, 26, 28, 31, 32). Our study found
a significant impact of PET/CT in the management of recur-
rent ovarian cancer (Table 8). The therapeutic procedures were
changed in 30/53 of our cases (56.6%), which is comparable with
the previously published studies of Bilici – 51.6%, Ebina – 58.4%,
Fulham – 58.9%, Hebel – 69%, and Rousseau – 71.5% (6, 7, 9, 33,
34).
Despite its high accuracy (80%) in the diagnosis of ovarian
cancer recurrence (35), CA 125 has its limits. While a normal
value cannot exclude the presence of disease, an increase of CA
125, even in normal limits, can predict recurrence. According to
a study of Bhosale et al., PET/CT detected recurrence in 58% of
TABLE 7 | Sensitivity of PET/CT in the detection of recurrent ovarian cancer:
comparison with previously published data.
Studies No. pts Sensitivity PET/CT (%)
Gu et al. (5) 882 91
Gouhar et al. (23) 39 90
Rubini et al. (31) 79 85
Hebel et al. (9) 48 97
Takeuki et al. (11) 48 94
Risum et al. (25) 60 97
Antunovic et al. (26) 121 82
Sanli et al. (28) 47 97:5
Sari et al. (32) 34 96:1
Bilici et al. (6) 60 95
Our study 42 92:2
TABLE 8 | Impact of PET/CT in themanagement of recurrent ovarian cancer:
comparison with previously published data.
Studies No. pts Change of treatment (%)
Fulham et al. (7) 90 58.9
Hebel et al. (9) 48 69
Bilici et al. (6) 60 51.6
Rousseau et al. (33) 34 71.5
Ebina et al. (34) 44 58.4
Our study 42 56.6
cases whenCA125was normal, while 31% of patients with normal
CA125 and negativeCThad ovarian cancer recurrence confirmed
by histology (36). Furthermore, high values cannot differentiate
local recurrence from distant metastases (14, 31). It is the role of
imagery, and especially PET/CT, to answer that question.
Our study has several limitations. First, it is a retrospective
study with potential inherent biases, and further prospective stud-
ies are needed to confirm the results. Second, the ideal gold
standard for any analysis is histological confirmation (n= 16/53).
However, clinical follow-up (n= 37/53) is also a valid way to
evaluate diagnostic accuracy and response to therapy, but it would
have been unethical to investigate all PET/CT detected foci using
invasive procedures. Finally, the number of patients in the study
was relatively small and it warranted the necessity to gather
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patients for survival analysis in order to retain a valid and strong
power by statistical analysis.
Conclusion
In recurrent ovarian carcinoma suspected by elevated CA 125
serum levels and normal or dubious CT, FDG PET/CT provides
staging information that more accurately stratifies prognostic risk
in recurrence ovarian cancer when compared with CT alone.
There is also a strong evidence to support the use of PET/CT
not only for the detection of recurrent ovarian cancer but also
to confirm recurrence from the point of view of the therapeutic
outcome (choice of treatment). Nonetheless, further evaluations
appear necessary.
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